What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)”In the company’s words, NCT05320588 on ClinicalTrials.gov
- Tested for
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Main trialPhase 1/2
- “A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.”In the company’s words, NCT05320588 on ClinicalTrials.gov
Other drugs for Advanced Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Apr 2024 | A Study in Patients With Advanced Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026